Safety and efficacy of an extended‐release peptide YY analogue for obesity: A randomized, placebo‐controlled, phase 1 trial
Open Access
- 19 February 2021
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (7) , 1471-1483
Abstract
Aim: To report the results from a Phase 1 trial of an extended‐release peptide YY analogue, Y14, developed for the treatment of obesity. Methods: Y14 was evaluated in overweight/obese volunteers in a Phase 1 randomized placebo‐controlled trial, conducted in a clinical trial unit in the United Kingdom. Part A was a blinded single‐ascending‐dose study evaluating doses up to 36 mg. Part B was double‐blinded and tested multiple ascending doses between 9 and 36 mg, given at 7‐ to 14‐day intervals, over the course of 28 days, with up to five doses given per participant. The primary outcome was safety and tolerability; the secondary outcome was assessment of pharmacokinetic (PK) characteristics. Exploratory outcomes included food intake, body weight change and glucose tolerance after multiple doses. Results: Between April 11, 2017 and December 24, 2018, 53 participants were enrolled into Part A and 24 into Part B of the trial. The PK characteristics were compatible with administration every 7 to 14 days. The most common adverse events (AEs) were nausea, vomiting or administration site reactions, which were mild in most cases and settled with time. No serious AE occurred. Participants given multiple doses of Y14 lost between −2.87 and −3.58 kg body weight compared with placebo ( P P <0.0001, compared to placebo) and there was no evidence of tachyphylaxis. Conclusions: Our results support the continued development of Y14 as a novel treatment for obesity.Keywords
This publication has 21 references indexed in Scilit:
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse EventsJAMA, 2016
- How common is hypoglycemia after gastric bypass?Obesity, 2016
- Combination of Peptide YY3–36with GLP-17–36 amideCauses an Increase in First-Phase Insulin Secretion after IV GlucoseThe Journal of Clinical Endocrinology & Metabolism, 2014
- Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgeryJournal of Internal Medicine, 2013
- A Review of Adult Mortality Due to 2009 Pandemic (H1N1) Influenza A in CaliforniaPLOS ONE, 2011
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese malesAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese AdultsThe Journal of Clinical Endocrinology & Metabolism, 2007
- Inhibition of Food Intake in Obese Subjects by Peptide YY3–36New England Journal of Medicine, 2003
- Gut hormone PYY3-36 physiologically inhibits food intakeNature, 2002